An important method for preventing and controlling influenza virus infection is the influenza vaccine. The most widely used commercially available and experimental influenza vaccines are inactivated whole virus vaccines, split-virion vaccines, subunit vaccines, virosome influenza vaccines, live attenuated vaccines, and recombinant live viral vector vaccines.
The development of therapeutically effective vaccines has been made possible by rising government funding, which has also increased support for and surveillance of influenza vaccination at the national and international levels to track the supply, distribution, and administration of flu vaccines. This has led to an increase in investment by top market players globally.
A Comprehensive Analysis:
In recent years, the influenza vaccine market has witnessed a series of product launches and approvals that have contributed to its growth.
DataM Intelligence's in-depth market analysis reveals the major market drivers, challenges, and trends. Our market intelligence report evaluates the market size, growth, and share, providing crucial insights for businesses to make informed decisions and capitalize on the existing and upcoming opportunities in the influenza vaccine market.
Influenza Vaccines Market Dynamics:
Increasing Number of Government Investments:
One of the key factors influencing the market's future growth is the increase in government investment. For instance, the seasonal influenza vaccination received more than $100 million in funding from the Australian government in March 2022 to safeguard people who are vulnerable. Large pharmaceutical companies are also devoting a lot of time and energy to developing improved therapies in the form of vaccines.
- For instance, Seqirus invested in self-amplifying mRNA, the next-generation influenza vaccine technology, in August 2021. The company intended to launch clinical trials for influenza vaccines against both seasonal and pandemic strains.
High Cost of Vaccines on the Influenza Vaccines Market:
It is anticipated that the high cost of vaccine development will impede market expansion throughout the forecast period.
- For example, on June 22, 2021, the scientific journal BMJ published an article about expensive vaccines. Through partnerships, the Centers for Disease Control and Prevention (CDC) ordered mass vaccination for the influenza season of 2020-2021. The CDC purchased seven million doses directly from manufacturers at a cost of IJS$ 100 million per dose, an increase from previous years.
Top Companies in the Influenza Vaccines Market:
These businesses concentrate on product innovation, quality control, marketing tactics, and distribution network growth to keep a competitive advantage in the market. Players often use partnerships, collaborations, mergers, and acquisitions to improve their market positions.
The major global players in the influenza vaccines include
- AstraZeneca PLC
- CSL Limited
- Abbott Laboratories
- Emergent BioSolutions
To Know More Insights Download Sample
